Arch Therapeutics (ARTH) Given a $3.00 Price Target by HC Wainwright Analysts

Arch Therapeutics (OTCMKTS:ARTH) received a $3.00 target price from equities researchers at HC Wainwright in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the biotechnology company’s stock.

A number of other research analysts also recently commented on ARTH. ValuEngine downgraded Arch Therapeutics from a “hold” rating to a “sell” rating in a research note on Friday, November 17th. Zacks Investment Research raised Arch Therapeutics from a “hold” rating to a “buy” rating and set a $0.75 price target for the company in a research note on Friday, December 1st. Finally, Ifs Securities upgraded Arch Therapeutics from an “outperform” rating to a “strong-buy” rating in a research report on Monday, February 5th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $2.17.

Arch Therapeutics (OTCMKTS:ARTH) opened at $0.32 on Thursday. The company has a market capitalization of $46.99, a PE ratio of -8.00 and a beta of 0.52. Arch Therapeutics has a 52 week low of $0.25 and a 52 week high of $0.89.

TRADEMARK VIOLATION WARNING: This report was originally posted by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally stolen and republished in violation of U.S. and international trademark & copyright legislation. The original version of this report can be accessed at

About Arch Therapeutics

Arch Therapeutics, Inc is a development-stage company. The Company operates as a biotechnology company. The Company focuses on developing products to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. The Company’s technology is based on a self-assembling peptide that creates a physical, mechanical barrier, which could be applied to seal organs or wounds that are leaking blood and other fluids.

Receive News & Ratings for Arch Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arch Therapeutics and related companies with's FREE daily email newsletter.

Leave a Reply